

## Patients' and consumers' organisation funding sources

**NAME OF ORGANISATION:** European Society of Oncology Pharmacy (ESOP)

**YEAR:** 2017

Industry <sup>1</sup> related income <sup>2</sup>		
Name of company/ funder	Amount of income	% of overall organisation's income
BBRAUN (MC)	3.000,00	2,79 %
NOVARTIS (NHD)	4.397,82	4,10 %
TEVA (MC)	1.768,00	1,65 %
CODAN (MC)	1.500,00	1,40 %
BBRAUN (NHD)	1.000,00	0,93 %
ICU (MC)	1.500,00	1,40 %

<sup>1</sup> Industry is defined as commercial manufacturers of healthcare products and services, including distributors and wholesalers, etc.

<sup>2</sup> This should reflect the overall funding received from industry, including, e.g. projects, conferences, etc.

EQUASHIELD	1.500,00	1,40 %
CODAN	800,00	0,53 %
NOVARTIS	10.000,00	9,32 %
<b>Subtotal:</b>	24.465,82	22,79 %

### Non-industry related income

Source of funding <sup>3</sup>	Amount of income	% of overall organisation's income
ECOP 2016 Receipts final balance (participants)	9.633,21,14	8,97 %
MasterClass (MC) Receipts (participants)	29.811,41	27,77 %
ESO Grant (MC)	15.000,00	13,97 %
EC Grant (EPIC Poject)	27.414,40	25,54 %
Membership fees	875,00	0,82 %
Bank interests	144,35	0,13 %
<b>Subtotal:</b>	82.878,37	77,21 %

<sup>3</sup> E.g. membership fees, donations.

<b>TOTAL<sup>4</sup>:</b>	107.344,19	100 %
---------------------------	------------	-------

---

<sup>4</sup> In case the total figures in this table do not match those in the financial statement, please provide justification (attached here or as an email).

Information required to be included on organisation's website	Please include links below:
<ul style="list-style-type: none"> <li>Funding sources <b>Industry Sponsoring concerns European Congress of Oncology Pharmacy (ECOP), Masterclass and Neighbourhood day</b></li> </ul>	
<ul style="list-style-type: none"> <li>Overall proportion of industry and non-industry: <b>Industry 22,79 % Non-Industry 77,21 %</b></li> </ul>	
<ul style="list-style-type: none"> <li>Percentage of the highest contribution from a single company: <b>13,42 % (NOVARTIS)</b></li> </ul>	

**Comments/explanatory notes:**

When completing the form you may refer to the guidance document here (in particular point 4, pages 8-9):

[http://www.ema.europa.eu/docs/en\\_GB/document\\_library/Regulatory\\_and\\_procedural\\_guideline/2015/05/WC500187018.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2015/05/WC500187018.pdf)